In breast cancer, the type of treatment depends on the hormone receptors, Her2, and the clinical-pathological variables, including tumor size, tumor grade, and lymph node involvement status (López-Knowles et al., 2010; Wang et al., 2015). This evidence concerns the gene NR4A1 and breast cancer.